The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Demand for 5,000 L single-use bioreactors is on the rise among biopharma manufacturers. Here’s why.
This white paper explores why 5,000 L single-use bioreactors help bridge the gap between small-scale flexibility and commercial-scale capacity, better meeting biologics development needs.
When scaling biologics from clinical to commercial production, biopharma companies face a difficult choice: investing in inflexible 10,000–15,000 L stainless steel systems that lock them into fixed capacity or scaling out with multiple 2,000 L single-use bioreactors that increase complexity and costs. Both options waste resources—either through unused capacity or through operational inefficiency.
The 5,000 L single-use bioreactor offers an ideal middle ground
By bridging the gap between small-scale flexibility and commercial-scale capacity, it offers the agility to scale up or down as demand shifts while eliminating the cleaning validation, changeover delays, and capital commitment of stainless steel. For the 80% of biologics requiring less than 750 kg/year production, the 5,000 L “sweet spot” matches actual needs without over- or under-investing.
Download the white paper to discover:
- Why volatile biopharma markets demand manufacturing flexibility that stainless steel systems can't provide
- How 5,000 L single-use bioreactors deliver superior economics for products in the 30–150 kg/year demand range
- Real-world scale-up data showing consistent performance from 50 L to 5,000 L across multiple molecules
- How DynaDrive's 20:1 turndown ratio and enhanced mass transfer support both clinical and commercial manufacturing
Watch this video to see our 5,000 L HyPerforma Single-Use Bioreactors (S.U.B.s) in action, and now available at our state-of-the-art St. Louis, Missouri, US and Lengnau, Switzerland biologics manufacturing facilities.
Helpful resources
Webinar
Scaling smart: Overcoming the top roadblocks in biologic drug manufacturing
This on-demand webinar explores how a unified, global CDMO model can help biologic drug developers overcome the most pressing challenges in clinical and commercial manufacturing.
Webinar
Strategies for robust process characterization and validation to accelerate biologics manufacturing
Learn how robust data-driven process characterization and validation can reduce risk and accelerate biologics manufacturing through real-world examples.
Whitepaper
Sustainable systems: Evaluating the environmental impact of single-use biomanufacturing technology
This whitepaper explores the advantages of sustainability with respect to single-use bioreactors, buffer and media hold containers, centrifuges and other biomanufacturing equipment.